BrainsWay invests additional $6M milestone-based in Neurolief — strategic deep TMS + at-home stimulation partnership
Summary
BrainsWay completed a $6M milestone-based investment in Neurolief, makers of the FDA PMA-approved Relivion at-home brain stimulation device for depression. The investment creates a strategic relationship between BrainsWay's clinic-based deep TMS system and Neurolief's home-based stimulation platform, potentially enabling a combined treatment pathway where BrainsWay initiates acute treatment and Neurolief maintains it at home.
Why it matters
A milestone-based investment signals BrainsWay is pricing in specific Neurolief performance milestones — likely related to commercial uptake of Relivion following FDA PMA. This structuring protects BrainsWay if adoption is slow while positioning them to benefit from Neurolief's commercial success through a combined treatment narrative that differentiates both companies.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial